– Recommended Phase 2 Dose for IGM-2323 Expected in 2021 – – Initial Data from Phase 1 Trial of IGM-8444 in Solid Cancers Expected in 2021 – – IND Filing for IGM-7354 Planned in 2021 – – Company to Host Conference Call Today at 4:30 p.m. ET – MOUNTAIN VIEW, Calif.

MOUNTAIN VIEW, Calif. , March 24, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences , Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that it will report its fourth quarter and year-end 2020 financial results on

– Ms. Decker Brings 20 Years of Development Experience in the Life Sciences Industry – MOUNTAIN VIEW, Calif. , March 15, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (IGM), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the

MOUNTAIN VIEW, Calif. , Feb. 05, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer , Chief Executive Officer, will participate in a fireside chat at

- IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors - MOUNTAIN VIEW, Calif. , Jan. 11, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS) today announced that it has entered into an exclusive license agreement with Medivir AB (Nasdaq Stockholm:

MOUNTAIN VIEW, Calif. , Jan. 07, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences , Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer , Chief Executive Officer, will present at the 39th Annual J.P.